Open Access. Powered by Scholars. Published by Universities.®

Cancer Biology Commons

Open Access. Powered by Scholars. Published by Universities.®

Articles 1 - 3 of 3

Full-Text Articles in Cancer Biology

Can Pancreatic Cancer Be Controlled By Cellular Immunity?, Kirby Robbins, John Harms, Lawrence Mylin Jan 2017

Can Pancreatic Cancer Be Controlled By Cellular Immunity?, Kirby Robbins, John Harms, Lawrence Mylin

Honors Projects and Presentations: Undergraduate

Pancreatic cancer is aggressive and poorly understood with a five-year survival rate of only 9% because most cases are diagnosed at a late stage. Because of ambiguous symptoms, pancreatic cancer is very difficult to detect early, and often when it is finally diagnosed, the cancer has already metastasized or has become too robust to cure. Current treatments are largely ineffective, so there is a great need for a novel approach to targeting this debilitating disease. To determine whether an intracellular peptide target expressed only in pancreatic cancer cells can be utilized to control or eradicate pancreatic cancer tumors by T ...


Increasing The Stability And Expression Of Green Fluorescent Protein In Pancreatic Cancer Cells For Metastasis Assays, Holly M. Ross, John F. Harms Jan 2016

Increasing The Stability And Expression Of Green Fluorescent Protein In Pancreatic Cancer Cells For Metastasis Assays, Holly M. Ross, John F. Harms

Honors Projects and Presentations: Undergraduate

Pancreatic cancer is the fourth leading cause of cancer death in the United States, with only 11% of patients diagnosed with metastatic disease surviving the first year. Even so, few studies exist to characterize the mechanism of metastasis in this highly aggressive form of cancer. Consequently, it is imperative that techniques, such as tagging cells with green fluorescent protein (GFP), are developed to track cancerous cells over the course of their spread. Unfortunately, the existing GFP vector contains a cytomegalovirus promotor, which is readily silenced by cells and decreases the vector’s usefulness for long-term studies in vivo. It was ...


T-Cell Treatments For Solid And Hematological Tumors, Drew C. Deniger Aug 2013

T-Cell Treatments For Solid And Hematological Tumors, Drew C. Deniger

UT GSBS Dissertations and Theses (Open Access)

Cell-based therapies have demonstrated potency and efficacy as cancer treatment modalities. T cells can be dichotomized by their T cell receptor (TCR) complexes where alpha/beta T cells (95% of T cells) and gamma/delta T cells (+T cells proliferated to clinically significant numbers and ROR1+ tumor cells were effectively targeted and killed by both ROR1-specific CAR+ T cell populations, although ROR1RCD137 were superior to ROR1RCD28 in clearance of leukemia xenografts in vivo. The second specific aim focused on generating bi-specific CD19-specific CAR+ gamma/delta T cells with polyclonal TCRgamma/delta repertoire on CD19+ artificial antigen presenting cells (aAPC). Enhanced ...